一名难以控制的银屑病患者在接受ixekizumab治疗后继发炎症性肠病。

IF 2.7 4区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Revista Espanola De Enfermedades Digestivas Pub Date : 2025-02-01 DOI:10.17235/reed.2024.10290/2024

Eugenia Navarro Moreno, Marta Lázaro Sáez, José Luis Vega Sáenz

{"title":"一名难以控制的银屑病患者在接受ixekizumab治疗后继发炎症性肠病。","authors":"Eugenia Navarro Moreno, Marta Lázaro Sáez, José Luis Vega Sáenz","doi":"10.17235/reed.2024.10290/2024","DOIUrl":null,"url":null,"abstract":"Both psoriasis and inflammatory bowel disease (IBD) are immunomediated diseases. Some of their therapeutic tools are monoclonal antibodies. Ixekizumab is an interleukin-17 (IL-17) inhibitor approved for the treatment of psoriasis. Cases of IBD onset have been reported in patients treated with this drug. We present the case of a 35-year-old patient with the onset of ulcerative colitis (UC) type of IBD after starting ixekizumab treatment.","PeriodicalId":21342,"journal":{"name":"Revista Espanola De Enfermedades Digestivas","volume":" ","pages":"113-114"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Inflammatory bowel disease secondary to treatment with ixekizumab in a patient with difficult-to-manage psoriasis.\",\"authors\":\"Eugenia Navarro Moreno, Marta Lázaro Sáez, José Luis Vega Sáenz\",\"doi\":\"10.17235/reed.2024.10290/2024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Both psoriasis and inflammatory bowel disease (IBD) are immunomediated diseases. Some of their therapeutic tools are monoclonal antibodies. Ixekizumab is an interleukin-17 (IL-17) inhibitor approved for the treatment of psoriasis. Cases of IBD onset have been reported in patients treated with this drug. We present the case of a 35-year-old patient with the onset of ulcerative colitis (UC) type of IBD after starting ixekizumab treatment.\",\"PeriodicalId\":21342,\"journal\":{\"name\":\"Revista Espanola De Enfermedades Digestivas\",\"volume\":\" \",\"pages\":\"113-114\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola De Enfermedades Digestivas\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.17235/reed.2024.10290/2024\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Enfermedades Digestivas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17235/reed.2024.10290/2024","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

银屑病和炎症性肠病（IBD）都是免疫介导疾病。它们的一些治疗工具是单克隆抗体。Ixekizumab 是一种白细胞介素-17（IL-17）抑制剂，已被批准用于治疗银屑病。有报告称，接受该药物治疗的患者中出现了 IBD 发病病例。我们报告了一例 35 岁的患者在开始接受伊昔单抗治疗后出现溃疡性结肠炎（UC）型 IBD 的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Inflammatory bowel disease secondary to treatment with ixekizumab in a patient with difficult-to-manage psoriasis.

Both psoriasis and inflammatory bowel disease (IBD) are immunomediated diseases. Some of their therapeutic tools are monoclonal antibodies. Ixekizumab is an interleukin-17 (IL-17) inhibitor approved for the treatment of psoriasis. Cases of IBD onset have been reported in patients treated with this drug. We present the case of a 35-year-old patient with the onset of ulcerative colitis (UC) type of IBD after starting ixekizumab treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista Espanola De Enfermedades Digestivas 医学-胃肠肝病学

CiteScore

2.00

自引率

25.00%

发文量

400

审稿时长

6-12 weeks

期刊介绍： La Revista Española de Enfermedades Digestivas, Órgano Oficial de la Sociedad Española de Patología Digestiva (SEPD), Sociedad Española de Endoscopia Digestiva (SEED) y Asociación Española de Ecografía Digestiva (AEED), publica artículos originales, editoriales, revisiones, casos clínicos, cartas al director, imágenes en patología digestiva, y otros artículos especiales sobre todos los aspectos relativos a las enfermedades digestivas.